Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial

Nature Medicine

Volumn 13, Issue 9, 2007, Pages 1102-1107

  Patil, Sandeep T ^a,l   Zhang, Lu ^a   Martenyi, Ferenc ^b   Lowe, Stephen L ^c   Jackson, Kimberley A ^a   Andreev, Boris V ^d   Avedisova, Alla S ^e   Bardenstein, Leonid M ^f   Gurovich, Issak Y ^g   Morozova, Margarita A ^h   Mosolov, Sergey N ^g   Neznanov, Nikolai G ⁱ   Reznik, Alexander M ^j   Smulevich, Anatoly B ^h   Tochilov, Vladimir A ^k   Johnson, Bryan G ^a   Monn, James A ^a   Schoepp, Darryle D ^a,m  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly Area Medical Center Vienna   (Austria)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

^e Serbsky State Scientific Center of Social and Forensic Psychiatry   (Russian Federation)

^f A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^g Moscow Research Institute of Psychiatry   (Russian Federation)

^h MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

ⁱ Bekhterev St Petersburg Psychoneurological Research Institute   (Russian Federation)

^j Moscow Regional Psychiatry Hospital #5   (Russian Federation)

^k NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^l TAKEDA PHARMACEUTICALS   (United States)

^m MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LAMOTRIGINE; LY 2140023; LY 404039; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; OLANZAPINE; PLACEBO; PROLACTIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; AKATHISIA; ANXIETY; ARTICLE; ASTHENIA; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INSOMNIA; LABORATORY TEST; MALE; MENTAL INSTABILITY; MULTICENTER STUDY; NAUSEA; NEGATIVE SYNDROME; PARKINSONISM; PERIODONTITIS; PHASE 2 CLINICAL TRIAL; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RODENT; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; VITAL SIGN; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BICYCLO COMPOUNDS, HETEROCYCLIC; CYCLIC S-OXIDES; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; HUMANS; PLACEBOS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

ANIMALIA; RODENTIA;

EID: 34948858402     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1632     Document Type: Article

References (30)

1. Andreasen, N.C. & Carpenter, W.T., Jr. Diagnosis and classification of schizophrenia. Schizophr. Bull. 19, 199-214 (1993).
2. Tamminga, C.A. & Lahti, A.C. The new generation of antipsychotic drugs. Int. Clin. Psychopharmacol. 11, 73-76 (1996).
3. Rorick-Kehn, L.M. et al. Pharmacological and pharmacokinetic properties of a structurally-novel, potent, selective mGlu2/3 receptor agonist: in vitro characterization of LY404039. J. Pharmacol. Exp. Ther. 321, 308-317 (2007).
4. Schoepp, D.D., Jane, D.E. & Monn, J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38, 1431-1476 (1999).
5. Schoepp, D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299, 12-20 (2001).
6. Large, C.H., Webster, E.L. & Goff, D.C. The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl.) 181, 415-436 (2005).
7. Kremer, I. et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol. Psychiatry 56, 441-446 (2004).
8. Tuominen, H.J., Tiihonen, J. & Wahlbeck, K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 72, 225-234 (2005).
9. Goff, D.C. et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl.) 179, 144-150 (2005).
10. Heresco-Levy, U. et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 57, 577-585 (2005).
11. Schoepp, D.D. & Marek, G.J. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Current Drug Targets. CNS & Neurological Disorders. 1, 215-225 (2002).
12. Swanson, C.J. & Schoepp, D.D. The group II metabotropic glutamate agonist LY379268 and clozapine reverse phencyclidine-induced behaviors in monoaminedepleted rats. J. Pharmacol. Exp. Ther. 303, 919-927 (2002).
13. Aghajanian, G.K. & Marek, G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Research. Brain Res. Brain Res. Rev. 31, 302-312 (2000).
14. Meltzer, H.Y. Neuropsychopharmacology: The Fifth Generation of Progress (eds. Davis, K.L., Charney, D., Coyle, J.T. & Nemeroff, C.) 819-831 (Lippincott Williams & Wilkins, 2002).
15. Marek, G.J., Wright, R.A., Schoepp, D.D., Monn, J.A. & Aghajanian, G.K. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther. 292, 76-87 (2000).
16. Aghajanian, G.K. & Marek, G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36, 589-599 (1997).
17. Marek, G.J., Wright, R.A., Gewirtz, J.C. & Schoepp, D.D. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience 105, 379-392 (2001).
18. Gewirtz, J.C. & Marek, G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23, 569-576 (2000).
19. Zhai, Y. et al. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 28, 45-52 (2003).
20. Ellenbroek, B.A. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol. Ther. 57, 1-78 (1993).
21. Svensson, L., Zhang, J., Johannessen, K. & Engel, J.A. Effect of local infusion of glutamate analogues into the nucleus accumbens of rats: an electrochemical and behavioural study. Brain Res. 643, 155-161 (1994).
22. Xi, Z.X. et al. Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. J. Pharmacol. Exp. Ther. 303, 608-615 (2002).
23. Hu, G., Duffy, P., Swanson, C., Ghasemzadeh, M.B. & Kalivas, P.W. The regulation of dopamine transmission by metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 289, 412-416 (1999).
24. Cartmell, J., Monn, J.A. & Schoepp, D.D. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus D-amphetamine motor behaviors in rats. J. Pharmacol. Exp. Ther. 291, 161-170 (1999).
25. Flor, P.J., Battaglia, G., Nicoletti, F., Gasparini, F. & Bruno, V. Neuroprotective activity of metabotropic glutamate receptor ligands. Adv. Exp. Med. Biol. 513, 197-223 (2002).
26. Fleischhacker, W.W., Meise, U., Gunther, V. & Kurz, M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr. Scand. Suppl. 382, 11-15 (1994).
27. Crawford, A.M., Beasley, C.M., Jr. & Tollefson, G.D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr. Res. 26, 41-54 (1997).
28. Johnson, M.P. & Chamberlain, M. Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268. Neuropharmacology 43, 799-808 (2002).
29. Kay, S.R., Opler, L.A. & Fiszbein, A. Positive and negative syndrome scale (PANSS) manual. (Multi-Health Systems, North Tonawanda, New York, USA, 1986).
30. Guy, W. ECDEU assessment manual for psychopharmacology, revised version. (US Department of Health, Education and Welfare, Bethesda, Maryland, USA, 1976).